Pro Medicus, a healthcare imaging software company, saw its stock surge 10.2% to A$193.82 on Tuesday after releasing strong full-year results. The company reported revenue of $261.7 million, a 22.9% increase, and underlying net profit after tax (NPAT) of $144.7 million, a 24.1% rise. This growth was further fueled by the signing of 10 new contracts worth at least $407 million, including a major 10-year deal with UC Health Colorado.
Key Highlights
- Revenue growth: 22.9%
- Underlying NPAT increase: 24.1%
- New contract value: at least $407 million
- 10-year deal with UC Health Colorado
Pro Medicus remains debt-free with a high EBIT margin of 74.9%, reflecting robust underlying demand for its imaging platform. The company's forward contract book reached A$1.34 billion over the next five years, a 41.3% rise within 12 months.
The strong results saw Pro Medicus outperform the broader market, where the ASX 200 moved little. With a five-year revenue compound annual growth rate (CAGR) of 29%, the company's future prospects look promising.
The fully-franked dividend was lifted by 25.5% to 69 cents per share, while reported NPAT more than doubled to $265.3 million. On a constant currency basis, underlying revenue, EBIT, and NPAT all grew around 30%, reflecting the company's robust underlying demand for its imaging platform.
Overall, Pro Medicus's strong full-year results and robust growth prospects make it an attractive investment opportunity for those looking to tap into the healthcare imaging software market.